P. Chinet-Charrot

666 total citations
11 papers, 238 citations indexed

About

P. Chinet-Charrot is a scholar working on Surgery, Reproductive Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, P. Chinet-Charrot has authored 11 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 6 papers in Reproductive Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in P. Chinet-Charrot's work include Ovarian cancer diagnosis and treatment (6 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). P. Chinet-Charrot is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). P. Chinet-Charrot collaborates with scholars based in France and Luxembourg. P. Chinet-Charrot's co-authors include J.E. Couette, A Goupil, Christine Chevreau, S. Hoffstetter, Gilles Chaplain, Frédéric Rolland, J Chauvergne, Frank Priou, B Giraud and D. Donnarieix and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Radiotherapy and Oncology.

In The Last Decade

P. Chinet-Charrot

10 papers receiving 232 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Chinet-Charrot France 7 152 73 63 57 49 11 238
Alan K. Muñoz United States 10 143 0.9× 114 1.6× 45 0.7× 35 0.6× 26 0.5× 12 332
Bruce A. Fine United States 7 157 1.0× 108 1.5× 26 0.4× 36 0.6× 14 0.3× 10 279
J. Leake United States 8 62 0.4× 20 0.3× 63 1.0× 24 0.4× 19 0.4× 9 294
Supul Hennayake United Kingdom 7 138 0.9× 99 1.4× 30 0.5× 110 1.9× 10 0.2× 26 285
Tatsuro Murase Japan 8 206 1.4× 61 0.8× 61 1.0× 75 1.3× 22 0.4× 23 315
Afsaneh Tehranian Iran 13 61 0.4× 28 0.4× 67 1.1× 21 0.4× 22 0.4× 43 370
P Øgreid Norway 10 255 1.7× 34 0.5× 67 1.1× 89 1.6× 17 0.3× 21 346
Connie S. DiMarco United States 9 137 0.9× 57 0.8× 65 1.0× 119 2.1× 17 0.3× 15 655
Miriam Deniz Germany 10 57 0.4× 36 0.5× 68 1.1× 7 0.1× 23 0.5× 24 207
Ralf Witthuhn Germany 4 251 1.7× 73 1.0× 34 0.5× 34 0.6× 5 0.1× 11 274

Countries citing papers authored by P. Chinet-Charrot

Since Specialization
Citations

This map shows the geographic impact of P. Chinet-Charrot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Chinet-Charrot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Chinet-Charrot more than expected).

Fields of papers citing papers by P. Chinet-Charrot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Chinet-Charrot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Chinet-Charrot. The network helps show where P. Chinet-Charrot may publish in the future.

Co-authorship network of co-authors of P. Chinet-Charrot

This figure shows the co-authorship network connecting the top 25 collaborators of P. Chinet-Charrot. A scholar is included among the top collaborators of P. Chinet-Charrot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Chinet-Charrot. P. Chinet-Charrot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Joly, Florence, Nadine Houédé, Sabine Noal, et al.. (2009). Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. Clinical Genitourinary Cancer. 7(2). E28–E33. 41 indexed citations
2.
Kurtz, Ellen S., Dominique Besson, Marion Deslandres, et al.. (2008). Cetuximab (Ce) + topotecan (Tc) + cisplatin (Cp) for the treatment (Tt) of advanced cervix cancer (ACC): A phase II GINECO trial. Journal of Clinical Oncology. 26(15_suppl). 5512–5512. 2 indexed citations
3.
Joly, Florence, Hugues Bourgeois, Anne Floquet, et al.. (2006). Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer. International Journal of Gynecological Cancer. 16(1). 77–82. 6 indexed citations
4.
Chinet-Charrot, P., Hugues Bourgeois, Alain Lortholary, et al.. (2005). Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial. Journal of Clinical Oncology. 23(16_suppl). 5043–5043.
5.
Joly, Florence, Nadine Tchen, Christine Chevreau, et al.. (2004). Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. Journal of Clinical Oncology. 22(14_suppl). 4619–4619. 7 indexed citations
6.
Fumoleau, P., N. Colombo, Pierre Kerbrat, et al.. (2002). Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) based chemotherapy. 21. 1 indexed citations
7.
Ramaioli, A., C Théodore, M.-J. Terrier-Lacombe, et al.. (2001). Non-Hodgkin’s lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres. Annals of Oncology. 12(9). 1313–1315. 44 indexed citations
8.
Joly, Florence, Jean‐François Héron, Pierre Kerbrat, et al.. (2000). High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecologic Oncology. 78(3). 361–368. 18 indexed citations
9.
Lhommé, C., P Vennin, Thierry Lesimple, et al.. (1999). A Multicenter Phase II Study with Triptorelin (Sustained-Release LHRH Agonist) in Advanced or Recurrent Endometrial Carcinoma: A French Anticancer Federation Study. Gynecologic Oncology. 75(2). 187–193. 36 indexed citations
10.
Chauvergne, J, et al.. (1996). [Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer].. PubMed. 83(4). 315–23. 5 indexed citations
11.
Rozan, R, Éliane Albuisson, B Giraud, et al.. (1995). Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiotherapy and Oncology. 36(2). 83–93. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alan K. Muñoz Breakdown of academic impact, for papers by Bruce A. Fine Breakdown of academic impact, for papers by J. Leake Breakdown of academic impact, for papers by Supul Hennayake Breakdown of academic impact, for papers by Tatsuro Murase Breakdown of academic impact, for papers by Afsaneh Tehranian Breakdown of academic impact, for papers by P Øgreid Breakdown of academic impact, for papers by Connie S. DiMarco Breakdown of academic impact, for papers by Miriam Deniz Breakdown of academic impact, for papers by Ralf Witthuhn
Rankless by CCL
2026